Comparison · NCT01206062-182583d3
Intensive Control of SBP vs Standard Control of SBP: Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intensive Control of SBP vs Standard Control of SBP: Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR. Trial comparisons, record NCT01206062-182583d3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01206062-182583d3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00752 | 0.00409 | 0.0138 | wilson | |
| Risk in group 2 | 0.00912 | 0.00522 | 0.0159 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0016 | -0.00917 | 0.00578 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.825 | 0.357 | 1.9 | log | |
| Odds ratio, group 1 over group 2 | 0.823 | 0.354 | 1.91 | log | |
| Number needed to treat, for one fewer participant with the outcome on Intensive Control of SBP than on Standard Control of SBP | 625 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intensive Control of SBP | Participants randomized into the Intensive BP arm had a goal of SBP \<120 mm Hg. 2-drug therapy initiated in most participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP \<120 mm Hg; at periodic visits: addition of another drug required if not at goal.~Intensive control of SBP: Use of once-daily antihypertensive agents was encouraged unless alternative frequency was necessary. One or more medications from the following classes of agents were provided by the study for use in managing participants in both groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics | 10 | 1,330 | OG000 |
| Group 2 | Standard Control of SBP | Participants randomized into the Standard arm had a goal of SBP \<140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP \<130 mm Hg @ 1 visit; \<135 mm Hg @ 2 consecutive visits~Standard control of SBP: The same medications used in the Intensive BP arm will be used for the Standard BP arm. | 12 | 1,316 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR
- Description
- Time frame
- 6 years
- Population
- Participants with CKD at baseline
Source ClinicalTrials.gov
Trial
- Title
- Systolic Blood Pressure Intervention Trial
- NCT number
- NCT01206062
- Phases
- NA
- Conditions
- Hypertension
- Interventions
- Intensive control of SBP, Standard control of SBP
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Results first posted
- 2017-12-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01206062?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01206062-182583d3